- Home
- FTEL vs APRE Comparison
FTEL vs APRE Comparison
Compare FTEL & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTEL
- APRE
- Stock Information
- Founded
- FTEL 2007
- APRE 2006
- Country
- FTEL Australia
- APRE United States
- Employees
- FTEL N/A
- APRE N/A
- Industry
- FTEL
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FTEL
- APRE Health Care
- Exchange
- FTEL Nasdaq
- APRE Nasdaq
- Market Cap
- FTEL 9.1M
- APRE 9.4M
- IPO Year
- FTEL 2023
- APRE 2019
- Fundamental
- Price
- FTEL $0.54
- APRE $1.50
- Analyst Decision
- FTEL
- APRE Strong Buy
- Analyst Count
- FTEL 0
- APRE 1
- Target Price
- FTEL N/A
- APRE $20.00
- AVG Volume (30 Days)
- FTEL 144.9K
- APRE 34.9K
- Earning Date
- FTEL 04-28-2025
- APRE 11-06-2025
- Dividend Yield
- FTEL N/A
- APRE N/A
- EPS Growth
- FTEL N/A
- APRE N/A
- EPS
- FTEL N/A
- APRE N/A
- Revenue
- FTEL $4,990,695.00
- APRE $841,012.00
- Revenue This Year
- FTEL N/A
- APRE N/A
- Revenue Next Year
- FTEL N/A
- APRE N/A
- P/E Ratio
- FTEL N/A
- APRE N/A
- Revenue Growth
- FTEL 29.02
- APRE N/A
- 52 Week Low
- FTEL $0.36
- APRE $1.41
- 52 Week High
- FTEL $49.50
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- FTEL 54.57
- APRE 39.26
- Support Level
- FTEL $0.39
- APRE $1.49
- Resistance Level
- FTEL $0.68
- APRE $1.66
- Average True Range (ATR)
- FTEL 0.06
- APRE 0.08
- MACD
- FTEL 0.02
- APRE 0.00
- Stochastic Oscillator
- FTEL 53.25
- APRE 2.86
About FTEL Fitell Corporation
Fitell Corp engages in primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiaries. It operates in two segments: online fitness equipment distribution and licensing business to service the large and growing boutique fitness sector of the broader health and fitness club industry. The majority fitness equipment business is conducted in Australia via its own e-commerce platform and, through third-party sites. Licensing service offers a turnkey solution for personal training studios and commercial gym chains. The company earns maximum of revenue for retail.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.